Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 14/20 | 0.46 |
| ▸ | HTR2B | P41595 | 12/20 | 0.46 |
| ▸ | HTR2A | P28223 | 9/20 | 0.46 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8911452 | 0.77 | DRD2 (0.56) | HTR2CHTR2BHTR2AADRB1DRD2 | |
| SCHEMBL988610 | 0.76 | SLC6A2 (0.57) | HTR2CHTR2BHTR2AADRB1SLC6A2 | |
| Hydrochloric Acid SCHEMBL27929443 | 0.75 | SLC6A2 (0.55) | HTR2CHTR2BHTR2AADRB1SLC6A2 | |
| Piperazine SCHEMBL28141935 | 0.73 | SLC6A4 (0.54) | HTR2CHTR2BHTR2AUSP2ADRB1 | |
| SCHEMBL7416026 | 0.73 | SLC6A2 (0.46) | HTR2CHTR2BHTR2ASLC6A2SLC6A4 | |
| Bicarbonate SCHEMBL11621262 | 0.71 | SLC6A2 (0.51) | HTR2CHTR2BHTR2AUSP2KMT2A | |
| SCHEMBL4146589 | 0.71 | HTR2C (0.59) | HTR2CHTR2BHTR2AGAASLC6A4 | |
| SCHEMBL31051771 | 0.71 | ADRB1 (0.59) | ADRB1 | |
| SCHEMBL532010 | 0.70 | KEAP1 (0.64) | HTR2AKEAP1MEN1USP2GAA | |
| Tert-Butyl Formate SCHEMBL27769927 | 0.69 | HTR2C (0.37) | HTR2CHTR2BHTR2AMEN1USP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11414410-B2 | Inhibitors of protein kinases | ALEXION PHARMACEUTICALS, INC. (US) | 2022-08-16 | — | — | US | disclosed |
| US-20200239458-A1 | INHIBITORS OF PROTEIN KINASES | ALEXION PHARMACEUTICALS, INC. | 2020-07-30 | — | — | US | disclosed |
| US-20180186783-A1 | INHIBITORS OF PROTEIN KINASES | ALEXION PHARMACEUTICALS, INC. | 2018-07-05 | — | — | US | disclosed |
| US-9868729-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2018-01-16 | — | — | US | disclosed |
| EP-2321283-B1 | 2,6-DIAMINO-PYRIMIDIN-5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS | PORTOLA PHARM INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-20150094298-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. | 2015-04-02 | — | — | US | disclosed |
| US-8937070-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2015-01-20 | — | — | US | disclosed |
| US-20140031361-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. | 2014-01-30 | — | — | US | disclosed |
| US-8501944-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2013-08-06 | — | — | US | disclosed |
| US-20120129867-A1 | INHIBITORS OF PROTEIN KINASES | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-8138339-B2 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| EP-2321283-A1 | 2, 6-DIAMINO-PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS | Portola Pharmaceuticals, Inc. (US) | 2011-05-18 | — | — | EP | disclosed |
| US-20090318407-A1 | Inhibitors of protein kinases | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-24 | — | — | US | disclosed |
| WO-2009145856-A1 | 2, 6-DIAMINO-PYRIMIDIN- 5-YL-CARBOXAMIDES AS SYK OR JAK KINASES INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318407-A1 | Inhibitors of protein kinases | SYK, BTK, JAK1 | HTR2C 1627/4885HTR2B 1818/4885HTR2A 2258/4885 |
| US-20120129867-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | HTR2C 1627/4885HTR2B 1818/4885HTR2A 2258/4885 |
| US-20200239458-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | HTR2C 1627/4885HTR2B 1818/4885HTR2A 2258/4885 |
| US-20180186783-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | HTR2C 1627/4885HTR2B 1818/4885HTR2A 2258/4885 |
| US-11414410-B2 | Inhibitors of protein kinases | MAP3K1, MAP3K20, MAP3K2 | HTR2C 4760/4885HTR2B 4815/4885HTR2A 4830/4885 |
| US-20140031361-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | HTR2C 1627/4885HTR2B 1818/4885HTR2A 2258/4885 |
| US-20150094298-A1 | INHIBITORS OF PROTEIN KINASES | SYK, BTK, JAK1 | HTR2C 1627/4885HTR2B 1818/4885HTR2A 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.